PMID- 22127466
OWN - NLM
STAT- MEDLINE
DCOM- 20130517
LR  - 20211021
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 32
IP  - 11
DP  - 2012 Nov
TI  - Clinical results for tocilizumab over one year in the clinical setting as 
      assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at 
      week 24 are predictive factors for CDAI.
PG  - 3631-7
LID - 10.1007/s00296-011-2256-5 [doi]
AB  - To investigate the clinical results of 1 year tocilizumab (TCZ) treatment of 
      rheumatoid arthritis patients in clinical practice by using the clinical disease 
      activity index (CDAI). Thirty-one patients with inadequate response to DMARDs, 
      including methotrexate (MTX), or TNF inhibitors received TCZ (8 mg every 4 
      weeks). The clinical responses were measured using the 28-joint disease activity 
      score (DAS28-ESR) and CDAI. Matrix metalloproteinase-3 (MMP-3) was assessed as a 
      serological biomarker. Mean baseline DAS28-ESR was 5.96, decreasing to 2.89 at 
      week 52 with a remission rate (DAS28-ESR < 2.6) of 35.5%. Mean baseline CDAI was 
      28.4, decreasing to 10.2 at week 52 with a remission rate (CDAI </= 2.8) of 22.6%. 
      Of patients whose CRP levels had fallen to below the limit of detection by week 
      12, 65.2% achieved remission or low disease activity as assessed by CDAI at week 
      52. Median baseline MMP-3 level was 165.7 ng/mL, decreasing to 79.5 ng/mL at week 
      52. A positive correlation was seen between CDAI at week 52 and MMP-3 level from 
      week 12 onward. About 50% of the patients treated with TCZ in clinical practice 
      achieved a low disease activity level at week 52 as assessed by CDAI, which does 
      not include acute-phase proteins. Our results suggested that CRP levels falling 
      to below the limit of detection by week 12 and MMP-3 </= 80.6 ng/mL at week 24 
      could predict low disease activity or remission at week 52 as assessed by CDAI.
FAU - Kaneko, Atsushi
AU  - Kaneko A
AD  - Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 
      National Hospital Organization, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001 
      Nagoya, Japan. a-kaneko@xj.commufa.jp
FAU - Kida, Daihei
AU  - Kida D
FAU - Saito, Kiwamu
AU  - Saito K
FAU - Tsukamoto, Masami
AU  - Tsukamoto M
FAU - Sato, Tomotaro
AU  - Sato T
LA  - eng
PT  - Journal Article
DEP - 20111130
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - I031V2H011 (tocilizumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
CIN - Rheumatol Int. 2014 Jul;34(7):1025-6. PMID: 23887618
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/*drug therapy
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Remission Induction/*methods
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2011/12/01 06:00
MHDA- 2013/05/18 06:00
CRDT- 2011/12/01 06:00
PHST- 2011/08/09 00:00 [received]
PHST- 2011/10/22 00:00 [accepted]
PHST- 2011/12/01 06:00 [entrez]
PHST- 2011/12/01 06:00 [pubmed]
PHST- 2013/05/18 06:00 [medline]
AID - 10.1007/s00296-011-2256-5 [doi]
PST - ppublish
SO  - Rheumatol Int. 2012 Nov;32(11):3631-7. doi: 10.1007/s00296-011-2256-5. Epub 2011 
      Nov 30.